What is it about?
Locally advanced non-small cell lung cancer comprises TNM stage IIIA-C. Accordingly these heterogeneous subtypes have different prognosis and require different interdisciplinary multimodality approaches. Immune-checkpoint inhibition after chemoradiotherapy is standard and part of multimodal trials with surgery. Exact staging, genetics, immunology and functional testing are important.
Featured Image
Photo by CDC on Unsplash
Why is it important?
Locally advance non-smal cell lung cancer is a heterogenous disease stage. Prognosis depends on the optimal interdisciplinary multimodality management.
Perspectives
Integration of immunitherapy and targeted therapy in an optimal local treatment strategy has the potential of improving prognosis substantially.
Professor Rudolf M. Huber
University of Munich and Thoracic Oncology Centre Munich
Read the Original
This page is a summary of: New developments in locally advanced nonsmall cell lung cancer, European Respiratory Review, May 2021, European Respiratory Society (ERS),
DOI: 10.1183/16000617.0227-2020.
You can read the full text:
Contributors
The following have contributed to this page
